145 results about "Mother cells" patented technology

The invention belongs to the technical field of biological medicine, and particularly relates to an engineered cell microvesicle and a delivery system based on the engineered cell microvesicle, the system realizes efficient preparation of 1-5 [mu] m cell microvesicles, and the cell microvesicles have a large space volume and can be used for preparing the cell microvesicles. The carrier can be used for loading and delivery of target protein, polypeptide and recombinase which are specifically expressed in mother cells. The system transfects mother cells through lentivirus transfection or plasmid transfection to further produce cell microvesicles, and the microvesicles can load more goods and inherit membrane proteins of the mother cells, and can also effectively load intracellular proteins to realize effective delivery. By virtue of good structural stability, high immunogenicity and excellent biocompatibility, the cell microvesicle reduces systematic toxic and side effects of a traditional carrier, is expected to become an effective drug delivery system, and has great application potential in the field of gene therapy.

The present invention addresses the problem of providing: a method for preparing hepatic lineage cells in a large amount and with high purity; and a method for preparing liver system cells which can achieve high graft survival rate in a living body.　The present invention provides: a hepatoblast proliferation promoter and a culture medium, each of which contains a ROCK inhibitor, a TGFβ signaling pathway inhibitor, a Wnt signaling pathway activator, and a growth factor; and a proliferation / culture method using the hepatoblast proliferation promoter or the culture medium.

The invention develops a double-line sequential targeted nano-drug delivery system, epigenetic regulation and traditional chemotherapy are combined, and the system is used for accurately and effectively treating acute myelogenous leukemia. The METTL3 inhibitor and the ROS-responsive daunorubicin prodrug are co-delivered in a single nano-drug, and the nano-preparation can realize continuous and double-path drug release according to the oxidation-reduction state in AML cells. In leukemia stem cells with low ROS level, STM2457 is released preferentially to induce differentiation and improve the ROS level of mitochondria, so that DA-ROS is activated, and the effect of delaying cytotoxicity is achieved. On the contrary, the AML mother cells with high ROS level can immediately trigger DA-ROS activation and release the two drugs at the same time, so that the tumor cells are directly killed. This ROS adaptive delivery strategy ensures spatial and temporal accuracy of drug release in heterogeneous AML cell populations.

In various embodiments, provided herein are host cells, methods, and pharmaceutical compositions comprising gastrodin, wherein the gastrodin is produced by a genetically modified plant or plant cell, fungal cell, yeast cell, insect cell, or bacterial cell. In certain embodiments, the present disclosure provides methods and compositions for the production of gastrodin. In yet other embodiments, the present disclosure provides enhanced cells and methods for producing gastrodin.

The invention provides a mother battery piece, a battery piece, a preparation method of the mother battery piece and a photovoltaic module. The battery piece comprises a first semiconductor substrate; the first doped semiconductor layer is arranged in the central region; the isolation groove is formed in the first isolation area and surrounds the central area; wherein the side surface comprises a first sub-surface, and the first sub-surface is connected with the groove wall of the isolation groove; the tunneling passivation contact structure is at least arranged on the second surface; the first passivation layer at least covers the first doped semiconductor layer, the isolation groove and the first sub-surface; wherein the first sub-surface and the second surface are both provided with a plurality of square tower footing structures, the difference between the side length of the largest square tower footing structure on the first sub-surface and the side length of the largest square tower footing structure on the second surface is a first numerical value, and the first numerical value is smaller than or equal to 15 microns. The battery efficiency can be improved, and the manufacturing cost can be reduced.

Certain substances (e.g., large molecules) that ordinarily cannot traverse the cell membrane of cells can be introduced into cells by applying an alternating electric field to the cell for a period of time, wherein the frequency of the alternating electric field is selected so that application of the alternating electric field increases permeability of the cell membrane. Once the permeability of the cell membrane has been increased, the substance is able to cross the cell membrane. This approach is particularly useful in the context of cancer cells (e.g., glioblastoma).

The present invention relates to aptamers that specifically bind to the extra-cellular domain of alpha7 / beta1 integrin dimers, conjugates or particles comprising said aptamers, in muscles cells such as skeletal muscle fibres and satellite cells, or in cells aberrantly expressing said domain e.g. tumour cells such as rhabdomyosarcoma (muscle-derived tumours), or glioblastoma cancer stem cells, as well as conjugates comprising said aptamers, therapeutic or diagnostic compositions comprising said conjugates or said aptamers, and their use as a medicament and in diagnostic methods.

The present invention relates to a medium composition for in vitro fertilization and / or in vitro culture comprising a compound represented by chemical formula 1 or a pharmaceutically acceptable salt thereof, and a method using same. The compound or composition suppresses reactive oxygen species and lipid peroxidation in ovarian granulosa cells to preventing cytotoxicity and mitochondrial dysfunction caused by apoptosis and ferroptosis, leading to an improvement in the quality of aged oocytes, and to increase the developmental rate and blastocyst formation rate of pre-implantation embryos, thereby improving the efficiency of in vitro fertilization. In addition, treatment with the medium composition during the vitrification process of in vitro–fertilized embryos improves re-expansion and survival rates, thereby reducing structural and metabolic damage. Accordingly, the present invention can be advantageously applied to an assisted reproductive technology for treating infertility and subfertility, and in vitro fertilization and / or in vitro culture for improving the propagation efficiency of livestock.

Methods and compositions for generating B lineage cells, such as plasmablasts, plasma cells, and protein producing or protein secreting B cells are disclosed. The methods can involve stage-specific differentiation from stem cells or stem cell-derived hematopoietic progenitor cells through one or more intermediates to B lineage cells, such as plasmablasts, plasma cells, and protein producing or protein secreting B cells.

Disclosed are methods and compositions for generating B lineage cells, such as plasmablasts, plasma cells, and protein-producing or protein-secreting B cells. The methods may relate to stage-specific differentiation from stem cells or stem-cell derived hematopoietic progenitors through one or more intermediates to B lineage cells, such as plasmablasts, plasma cells, and protein-producing or protein-secreting B cells.

This invention discloses an engineered CAR-T cell targeting HIF-1α and its application in tumor immunotherapy. The CAR-T cell expresses a chimeric antigen receptor regulated by the hypoxia-responsive element HRE promoter, with its extracellular domain specifically binding to HIF-1α and its intracellular domain employing the 4-1BB+CD3ζ signaling module. Simultaneously, through immune checkpoint knockout and cytokine / chemokine modification, it achieves hypoxia-dependent activation, anti-exhaustion, high infiltration, and strong killing effects. The CAR-T cells of this invention significantly improve the adaptability to the solid tumor microenvironment and therapeutic efficacy, reduce off-target toxicity, and can be used to prepare drugs for treating malignant tumors such as lung cancer, liver cancer, pancreatic cancer, colorectal cancer, and glioblastoma, possessing significant clinical translational value.

The application belongs to the technical field of biology and particularly relates to a functional recombinant Cas9 protein targeted to an ovocyte of Procambarus clarkii and application thereof. The protein is NLs-VgSP-Cas9-NLs. The application directly delivers the recombinant Cas9 protein, thereby reducing the risk of integration of exogenous genes. By specifically targeting the ovocyte, off-target effects on somatic cells can be avoided, the efficiency of editing of germ cells is improved, and early development or genetic manipulation can be conveniently studied. The ovocyte of Procambarus clarkii is large, the recombinant Cas9 protein is efficiently delivered by receptor-mediated endocytosis on the surface of the ovocyte, and the problem that microinjection of zygotes cannot be implemented is solved.

The present invention relates to a yeast cell, in particular a recombinant yeast cell, the cell lacking enzymatic activity needed for the NADH-dependent glycerol synthesis or the cell having a reduced enzymatic activity with respect to the NADH-dependent glycerol synthesis compared to its corresponding wild-type yeast cell, the cell comprising one or more heterologous nucleic acid sequences encoding an NAD+-dependent acetylating acetaldehyde dehydrogenase (EC 1.2.1.10) activity. The invention further relates to the use of a cell according to the invention in the preparation of ethanol.

The present invention belongs to the field of molecular biology and genetics, and in particular relates to a method for editing a bovine gene based on Pro-iCHI. The present invention provides a method for editing a bovine gene based on Pro-iCHI. Protamine is transiently expressed in gene-edited b-haSCs, which are then injected to mature oocytes to obtain reconstructed embryos. Protamine can eliminate abnormal DNA methylation resulting from oocyte intracytoplasmic haSCs injection and enable the nucli to compress into sperm-like structures, and the obtained bovine Pro-iCHI embryos can successfully develop into blastocysts, with a blastocyst rate comparable to that of the embryos obtained by in vitro fertilization. Moreover, in the present invention, a protamine-encoding gene is inserted into a Saccharomyces cerevisiae protein expression vector for transient expression, which ensures that abnormal DNA methylation is erased, without integration into the genome resulting in the insertion of exogenous genes.

The MYC and NMYC transcription factors (TFs) play a key role in cell proliferation and are overexpressed in most cancer cells. However, in normal cells their overexpression triggers safeguard mechanisms promoting cell death and cellular senescence, which are bypassed in cancer cells. Here, the inventors reveal that in normal cells MYC binds to the Inositol 1,4,5-Trisphosphate Receptor type 1 (ITPR1) gene and upregulates its expression, triggering an ER-mitochondria calcium (Ca2+) transfer, which is involved in MYC-induced cell death and senescence. Supporting a tumor suppressive role of MYC / ITPR1 axis, ITPR1 expression is generally decreased in cancer and reactivation of this pathway induces cancer cell death. Nevertheless, some cancer cells, generally expressing high levels of MYCN and / or MYC, also express high level of ITPR1, which correlates with high expression of BCL2, encoding an inhibitor of ITPR1. Strikingly, in high-risk MYCN-amplified neuroblastoma, ITPR1 expression is controlled by NMYC and its level correlates with worse patient survival. In these cells, blocking the interaction between BCL2 and ITPR1, via an BCL2-BH4 domain inhibitor induces mitochondrial Ca2+ accumulation and cell death, and decreases tumor size. Thus, the present invention relates to a method for treating MYChigh cancer, and in particular NMYC--amplified neuroblastoma in a subject by administering an BCL2-BH4 domain inhibitor.

This invention belongs to the medical field and establishes a clinically relevant mouse glioblastoma treatment model, obtaining "cured" mice. When these "cured" mice were re-challenged with tumors, the tumors spontaneously regressed, and the animals achieved long-term survival. This indicates that the "cured" mice acquired immunity to the tumor, and these mice are named "cured-immune" mice. Intracranial inoculation of tumor cells into the "cured-immune" mice specifically induced a microglia subset exhibiting high expression of the purinergic receptor P2ry12 gene. High ) and immune-boosting functional characteristics, P2ry12 infusion Hi Small glial subsets significantly prolonged the survival time of glioma-bearing mice. Compared with the control group, P2ry12 in "cured-immune" (LTS) mice was significantly reduced. High Ccl12 low Differentially expressed genes in microglial cell subsets are enriched in signaling pathways that promote immune function, hence P2ry12 High Ccl12 low Microglial cell subsets have therapeutic effects on gliomas.

A simpler and lower-cost method and associated hardware are described for recovering biopharmaceutical products from cell factories in higher yields by a liquid nitrogen-based pre-treatment of cell factories followed by gentler disintegration of cellular factories by tunable, pressurizing and de-pressurizing cycle with gaseous nitrogen. The cell factories are heterologous expression systems and could be based on plant cells, mammalian cells, algal cells, yeast cells or even bacterial cells. The pre-treatment step with liquid nitrogen softens the tougher cell wall structures thus enabling cells to be disrupted relatively easily during the gaseous nitrogen-based pressurizing / depressurizing cycle. This invention can enhance the yield of biopharmaceutical products from expression systems and reduce the overall cycle-time and further down-stream processing and polishing cost of biopharmaceutical products.

The present application relates to the technical field of biological medicine, and more particularly to a culture solution, a kit and an application for in-vitro maturation of aged oocytes. Through in-vitro experiments, the present application adds exogenous stromal cell-derived factor 1, establishes a culture system for in-vitro maturation of aged oocytes, and reveals the molecular mechanism of stromal cell-derived factor 1 playing a role through autophagy, thereby providing a new solution for improving the fertility of aged women and improving the success rate of assisted reproductive technology, and having important clinical application value.

The application provides application of MTA1 which is highly expressed in glioma stem cells (GSC) in treatment of glioblastoma (GBM). The application firstly proposes that GSC in GBM highly expresses MTA1 protein molecules, the highly expressed MTA1 is positively correlated with poor prognosis of GBM patients, and also promotes the stemness, cell proliferation and spheroid formation ability of GSC. Targeting the highly expressed MTA1 in GSC can inhibit the malignant progression of GBM. The application provides a new target and inhibitor for targeted treatment of GBM.

The present invention relates to aptamers that specifically bind to the extra-cellular domain of alpha7 / beta1 integrin dimers, conjugates or particles comprising said aptamers, in muscles cells such as skeletal muscle fibres and satellite cells, or in cells aberrantly expressing said domain e.g. tumour cells such as rhabdomyosarcoma (muscle-derived tumours), or glioblastoma cancer stem cells, as well as conjugates comprising said aptamers, therapeutic or diagnostic compositions comprising said conjugates or said aptamers, and their use as a medicament and in diagnostic methods.

[Problem] The first problem addressed by the present invention is to specify a previously unknown factor or a combination of previously unknown factors among factors or combinations thereof capable of efficiently producing egg-like cells obtained from pluripotent stem cells or the like. The second problem addressed by the present invention is to provide an egg-like cell and a method for efficiently producing same. [Solution] This method for producing an egg-like cell involves a step for introducing a factor into a cell, wherein the factor includes DLX6 or a nucleic acid encoding DLX6. This egg-like cell is derived from a human pluripotent stem cell and expresses PADI6.

The invention belongs to a cell culture technology in the field of biomedicine, and particularly relates to a liver organoid for traditional Chinese medicine screening and toxicity assessment and a construction method and application thereof. The construction method comprises the following steps: carrying out plane multiplication culture on pluripotent stem cells, then digesting and subculturing, and repeating to obtain a cell culture medium; a pluripotent stem cell group which is uniform in cell morphology and free of spontaneous differentiation is obtained; performing two-dimensional plane directional induction on the pluripotent stem cell population to enable cells to synchronously and uniformly receive differentiation signals to obtain hepatogenic mother cells; culturing the obtained hepatic mastocytes by using a culture medium E under a three-dimensional suspension condition to promote the specificity and balling of the hepatic lineage; the culture medium E is an Advanced DMEM / F12 which comprises 1 to 5 [mu] M of RA, 2 to 10 [mu] M of Y-27632, 0.5 to 1 [mu] M of beta-nicotinamide mononucleotide, 5 to 10 [mu] M of senkyunolide A, B27 and N2; and then replacing the culture medium to further mature and functionalize the hepatocytes to obtain the liver organoid, and the obtained liver organoid has high stability, high uniformity, good survival rate and mature hepatocyte functions.

The invention provides a preparation method of a double-layer functionalized PS / GO nanofiber membrane, which can realize co-immobilization of yeast and beta-galactosidase, and belongs to the technical field of material chemistry and food biology. According to the method, beta-galactosidase and saccharomyces cerevisiae are successfully fixed on a functionalized graphene oxide modified double-layer polystyrene nanofiber membrane through a packaging method and an adsorption method, monosaccharide-free galactooligosaccharide (GOS) is obtained in one step by taking lactose as a raw material, and a novel biological catalysis system integrating GOS biosynthesis and monosaccharide removal is successfully constructed. In the catalytic system, the hydrolysis activity of the immobilized beta-galactosidase and the transglycosidase activity are remarkably improved compared with free enzymes, and the synthesis efficiency of GOS is effectively improved through the high transglycosidase activity of the immobilized beta-galactosidase. After being treated by the immobilized yeast cells, the yield of the GOS is still kept at a relatively high level of 56%, and more than 90% of monosaccharide in the product is consumed by the yeast cells, so that the high-purity GOS is obtained. And the catalytic system can be repeatedly used for multiple times, and the beta-galactosidase still keeps the enzyme activity of 50% or more after being recycled for 20 times, so that the preparation and production cost of the GOS can be effectively reduced. According to the preparation method of the double-layer functionalized PS / GO nanofiber membrane and the co-immobilization method of the yeast and the beta-galactosidase, provided by the invention, high-efficiency and low-cost preparation of high-purity GOS can be realized.

The invention provides a preparation method and application of a saccharomyces cerevisiae strain with high flocculation efficiency, a specific gene is knocked out and transferred in by using a homologous recombination method through a gene engineering technology to modify a saccharomyces cerevisiae BY4741 strain, and the metabolic pathway and related performance of yeast are accurately regulated and controlled. The method comprises the following specific steps: knocking out the SNF11 gene of the saccharomyces cerevisiae BY4741 strain, restoring the SNF11-SS18 (QPGY) gene, and constructing to obtain the saccharomyces cerevisiae strain with high flocculation efficiency, so that the efficient aggregation of yeast cells in a fermentation tank is realized, the cell density is improved, the fermentation period is shortened, expensive equipment such as a centrifugal machine is avoided, the energy consumption is reduced, and the production cost is reduced. Therefore, the fermentation efficiency is remarkably improved, the production cost is reduced, and powerful technical support is provided for sustainable development of the alcoholic fermentation industry.

The invention relates to a biomarker combination for treating SHH subtype medulloblastoma, and aims to solve the problems that existing treatment targets are deficient, the curative effect is limited and precise treatment is insufficient. The invention reveals that an m6A-YTHDF2 signal axis is a novel treatment target of SHH-MB for the first time, the YTHDF2 regulates and controls the expression of a downstream target gene DENND2A through an m6A dependency mode, the high expression of the YTHDF2 is related to poor prognosis of a patient, and knock-down of the YTHDF2 can significantly inhibit the proliferation and balling ability of SHH-MB cells. According to the invention, the TET-ON regulated SHH-MB cell line capable of inducing to knock down YTHDF2 is constructed, and a tool is provided for drug screening; it is clear that a YTHDF2 inhibitor (such as DC-Y13-27 and the like) can achieve the anti-tumor effect by down-regulating DENND2A expression, and the drug sensitivity of SHH-MB tumor cells to a Hedgehog signal channel small molecule inhibitor Vismodegib (GDC-0449) is improved.

The application discloses a double-targeted glioma composite nanomaterial and a construction method thereof, wherein the composite nanomaterial comprises, from inside to outside, modified mesoporous silica, a drug loading layer, a hybrid membrane layer and a specific modification layer; and the hybrid membrane layer is obtained by combining liposomes and glioma-specific dendritic cell membranes. The double-targeted glioma composite nanomaterial can realize double targeting of glioma cells due to the existence of the hybrid membrane layer and the specific modification layer, has no obvious immunogenicity, can efficiently release preloaded molecules or drugs in cells, and is expected to develop into a new nanomaterial for more effective treatment of glioma.

The present application belongs to the technical field of biological medicine, and particularly relates to Hermetia illucens extract, an extraction method thereof and application thereof in preventing and treating tumors. The present application extracts polar components from Hermetia illucens powder, and the obtained Hermetia illucens extract has a significantly better inhibitory activity on the proliferation of Cal27 human tongue squamous cell carcinoma cells, Colo205 human colorectal cancer cells and U87 MG human brain astrocytoma cells than the Hermetia illucens powder without separation under the same mass concentration. In animal experiments, the Hermetia illucens extract can significantly prolong the survival cycle of MOC-1 tongue squamous cell carcinoma mice, and has a significantly better treatment effect than the Hermetia illucens powder and is close to the positive drug cisplatin.

It provides a bioengineered bacteriophage-lime nanoparticle, rQβ@b-3WJ, comprising a broccoli light-up aptamer including 3WJ RNA scaffold (b-3WJ) integrated with a nucleic acid bioproduction and self-packaging system to produce b-3WJ packaged Qβ VLPs. Also provided is a nanoparticle, TrQβ@b-3WJ, which is the TrQβ@b-3WJ with the conjugation of TAT peptide on the surface, which enhance cellular internalization for highly efficient gene silencing.

The invention belongs to the field of molecular biology and genetic engineering, and particularly relates to a method for constructing a soybean pollen mother cell meiosis abnormality mutant and application. According to the application, three PS1 genes GmPS1a, GmPS1b and GmPS1c of soybean are subjected to gene editing at the same time for the first time, the gene editing soybean three-gene homozygous mutant with changed amino acids of GmPS1a, mPS1b and GmPS1c is created, and the mutant shows the characteristic of meiosis abnormality of soybean pollen mother cells; and a good genetic resource is provided for research on a molecular regulation mechanism related to the meiosis process of the soybean pollen mother cells.

According to the application of the salidroside in preparation of the medicine for treating the Alzheimer's disease by relieving ferroptosis, the salidroside is used for relieving the ferroptosis of human neuroblastoma (SH-SY 5Y) cells induced by A [beta] 1-42 by inhibiting a voltage dependent anion channel 1 (VDAC1) and activating an AKT / GSK-3beta pathway, and the application of the salidroside in the preparation of the medicine for treating the Alzheimer's disease by relieving the ferroptosis of the human neuroblastoma (SH-SY 5Y) is realized by inhibiting the voltage dependent anion channel 1 (VDAC1) and activating the AKT / GSK-3beta pathway. The salidroside can relieve the ferroptosis of SH-SY 5 Y cells induced by A beta 1-42 under the optimal concentration of 30 mM. After salidroside treatment, the expression quantity of GPX 4 and FTH 1 is increased, and the expression quantity of IREB 2 is reduced. The cell apoptosis rate is reduced, and the Fe < 2 + > content and ROS level in cells are also reduced. After si-VDAC 1 is transfected, the change trend of si-VDAC 1 is similar to the trend after salidroside treatment. In addition, the treatment of an AKT inhibitor and an AKT activator shows that an AKT / GSK-3beta signal channel participates in the process of inducing the ferroptosis of the SH-SY 5 Y cells by the Abeta1-42.